Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Novartis
Teva
Fish and Richardson
Accenture
Boehringer Ingelheim
Argus Health
Chinese Patent Office
Mallinckrodt

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,703,156

« Back to Dashboard

Which drugs does patent 8,703,156 protect, and when does it expire?


Patent 8,703,156 protects FERRIPROX and is included in one NDA. There has been one Paragraph IV challenge on Ferriprox.

This patent has twenty-one patent family members in twenty-two countries.

Summary for Patent: 8,703,156

Title:Liquid formulation for deferiprone with palatable taste
Abstract: An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per liter of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per liter of liquid composition, an effective amount of a humectant (such as glycerin) per liter of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.
Inventor(s): Spino; Michael (Pickering, CA), Hui; Anita (Unionville, CA), Yang; Cihua (Richmond Hill, CA), Kabir; Mohammed N. (Richmond Hill, CA)
Assignee: Apotex Technologies Inc. (Toronto, Ontario, CA)
Application Number:12/989,127
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► SubscribeY METHOD OF TREATING CHRONIC IRON OVERLOAD
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,703,156

PCT Information
PCT FiledApril 25, 2008PCT Application Number:PCT/CA2008/000784
PCT Publication Date:October 29, 2009PCT Publication Number: WO2009/129592

International Patent Family for Patent: 8,703,156

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Costa Rica11744► Subscribe
Cyprus1116146► Subscribe
Denmark2268282► Subscribe
Eurasian Patent Organization201071235► Subscribe
Eurasian Patent Organization022751► Subscribe
European Patent Office2268282► Subscribe
Hong Kong1152871► Subscribe
CroatiaP20150083► Subscribe
Israel208876► Subscribe
South Korea20100135316► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
QuintilesIMS
Harvard Business School
McKinsey
Fuji
Chinese Patent Office
Mallinckrodt
Argus Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot